Engineered protein could be used to treat type 2 diabetes
An engineered form of the SMOC1 protein has shown success as a type 2 diabetes treatment in animal models, say researchers.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
An engineered form of the SMOC1 protein has shown success as a type 2 diabetes treatment in animal models, say researchers.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
Researchers have discovered compounds able to restart production of VEGF-A in cellular models, which rebuilds blood vessels and muscle in damaged heart tissue.
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
A molecule called TPPU has been shown to inhibit an enzyme that plays a key role in inflammation, successfully treating arthritis in mice.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
A new FXII inhibitor has been developed that efficiently blocked coagulation in a thrombosis model without increasing the risk of bleeding.
Researchers have created compounds called 3C-like protease inhibitors which demonstrated antiviral activity against several coronaviruses in cells, including COVID-19.
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.